Photo Gallery



News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • MARCH 2021 Issue has been successfully launched on 1 March 2021.



Y.Ganesh Kumar*, Ch.Anil kumar, D.Satyavati, B.Swetha, D.Narasimha Rao


Zolmitriptan is a Selective Serotonin receptor agonist of the 1B and 1D subtype. Used in the acute treatment of Migraine attacks with or without aura and headaches. The present research work is aimed at developing a Formulate and Evaluated of an Oro dispersible tablet dosage form of Zolmitriptan. The target of these new oral dissolving/disintegrating dosage forms have generally been pediatric, geriatric, bedridden and developmentally disabled patients and also patients with persistent nausea, who are in traveling, or who have little or no access to water are also good candidates for ODTs Direct Compression method was employed for blending of drug with polymers in the given ratio as a 9 formulations. The prepared powder blends were then compressed into tablets using the necessary Superdisintegrants (CCS, CP, and SSG) and Excipients. The tablets were evaluated for Weight variation, thickness, hardness, friability, Drug Content and Disintegrating Time (Sec) were subjected to a 10 minutes in vitro drug release studies (USP dissolution rate test apparatus II, 50 rpm, 370C 0.50C) using phosphate buffer, pH 6.8 as a dissolution medium (900ml). The amount of Zolmitriptan released from the tablet formulations at different time intervals was estimated using a UV spectroscopy method. The formulations that showed a considerable retardation of the drug release are considered promising. Among the nine formulations, F7 formulation containing Drug to Sodium Starch Glycollate (SSG) in ratio 1:1 is optimized based on its ability to till 7 mins of invitro dissolution time, and its % Cumulative Drug Release Of The 99% of dissolution study.

Keywords: Zolmitriptan, Sodium Starch Glycollate, Selective Serotonin receptor agonist, Migraine.

[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More